SLC5A2 and chronic kidney disease: Evidence-based treatments, including renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like finerenone, have shown marked effectiveness in delaying CKD progression and lowering the incidence of cardiovascular events [8,9].